Vivo funds (SABS) report capped 9.99% stakes via preferred stock and warrants
SAB Biotherapeutics, Inc. disclosed via an amended Schedule 13G that Vivo Opportunity Fund Holdings, L.P. and related entities may be deemed to beneficially own 22,637,108 shares and 2,286,301 shares, respectively. Holdings include common stock plus conversion/exercise shares from Series B Preferred and related warrants within 60 days, capped at 9.99% voting ownership by blocking provisions.
How this was made
The 30-second read
Why it matters
The main tradable implication is positioning and potential future share issuance from conversions/exercises within 60 days, but the voting cap reduces governance impact.
Market read
A large investor stake is disclosed with structured instruments (Series B Preferred, Enrollment Warrants, Data Release Warrants) and explicit 9.99% voting caps.
What to watch
Traders should focus on whether any subsequent filings (13D/13G amendments, conversion/exercise disclosures) occur, since the economic exposure can change even if voting power is capped.
Background
The article summarizes an amended Schedule 13G for SAB Biotherapeutics, detailing beneficial ownership through common stock plus Series B Preferred conversion and related warrants.
Ticker impact
SAB Biotherapeutics disclosed Vivo Opportunity’s amended Schedule 13G showing 9.99% capped beneficial ownership via Series B Preferred and warrants.
Near-term price impact is likely limited, but volatility risk can rise around any conversion or exercise activity within the 60-day window.
The article is a regulatory ownership disclosure, not a deal or operational update. The key incremental detail is the amended stake composition and the 9.99% blocking provisions that constrain voting power.
Market effects
For biotech, large capped stakes via preferred and warrants can indicate financing or strategic interest, but this filing alone does not confirm a new clinical or commercial catalyst.
none
none
Counterpoint
The 9.99% cap and blocking provisions suggest the holder is intentionally avoiding control thresholds, so the market may overreact to the headline stake size.
Key entities
- issuerSAB Biotherapeutics, Inc.
Company whose common stock and equivalents are subject to the amended Schedule 13G disclosure.
- investorVivo Opportunity Fund Holdings, L.P.
Reporting entity deemed to beneficially own 22,637,108 shares and equivalents, capped at 9.99% voting securities.
- investorVivo Opportunity Cayman Fund, L.P.
Reporting entity deemed to beneficially own 2,286,301 shares and equivalents, also capped at 9.99% voting securities.
